

## Special Issue

# COVID-19 and Vaccination Strategies in Global Health

### Message from the Guest Editor

We have faced challenging times since the beginning of the COVID-19 pandemic. It has affected us all in an unprecedented way, pushing medical authorities, pharmaceutical companies, scientists, patients, and their relatives to find and test solutions which could limit the spread of the Sars-Cov-2 virus or its consequences on our health and on our lives. As we all know, vaccines have played a major role, both in the scientific debate and in the attempt to contain the pandemic. The year 2022, the third year since the start of the pandemic, has provided an opportunity to update what we know, revise what we thought, and envisage what can be done further to manage pandemics such as COVID-19 and eventually prevent future ones. I therefore invite you all to contribute to this Special Issue of *Vaccines* on 'COVID-19 and Vaccination Strategies in Global Health' with original research articles, reports, and reviews. The scope of this Special Issue is purposefully wide, in order to tackle different points of view: immunology, infectiology, epidemiology, public health, primary care, and medical statistics.

### Guest Editor

Dr. Davide Barbieri

Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy

### Deadline for manuscript submissions

closed (31 March 2024)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/152381](https://mdpi.com/si/152381)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).